New hope for dizziness: CGRP drugs target vestibular migraine in major study
NCT ID NCT07203248
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test CGRP-targeted medications in 2,000 Chinese adults with vestibular migraine, a condition causing severe vertigo and dizziness. The goal is to see if these drugs can reduce the severity and frequency of attacks, both as immediate treatment and for prevention. Participants will track their symptoms daily, and researchers will measure how well the drugs work in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIZZINESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a symptom registry unmask hidden migraine variants?
- Wearable eye-tracker aims to catch dizziness in the act
- Can a new migraine drug stop the dizzy spells?
- Could a stick of gum soothe a spinning world?
- Can a Dual-Task test predict falls in the elderly?
- Wearable patch aims to catch hidden heart rhythms that holter monitors miss